Prostate Cancer Therapeutics - Global Market Outlook (2017-2023)

May 2017 | 148 pages | ID: PA5AA72978EEN
Stratistics Market Research Consulting

Abstracts

According to Stratistics MRC, the Global Prostate Cancer Therapeutics market is estimated at $XX million in 2016 and is expected to reach $XX million by 2023 growing at a CAGR of XX% from 2016 to 2023. Increase in prostate cancer cases in recent years and raise in development of innovative drugs are the some of the prominent factors driving the market growth. Whereas high cost and low success rate in the clinical test are hampering the market. However, increase in geriatric population and increase in R&D expenditure in this market seems to be opportunity for the market growth. In 2016, North America accounted for the highest market share owing to increase in research and development expenditure. The Asia Pacific region is expected to grow at a higher CAGR and is anticipated to account for the highest market share during forecast period because of government initiatives on creating awareness on prostate cancer.

Some of the key players in the market include Tolmar Inc, Teva Pharmaceutical Industries Ltd, Takeda Pharmaceutical Co. Ltd, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson, Ipsen, Ferring Pharmaceuticals, Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc), Dendreon Corporation, Bristol-Myers Squibb, Astrazeneca Plc, Astellas Pharma Inc, Active Biotech and Abbott Laboratories.

Drugs Classes Covered:

• Chemotherapy
• Estramustine (Emcyt)
• Mitoxantrone (Novantrone)
• Jevtana
• Taxotere
• Targeted Therapy
• Xofigo
• Hormonal Therapy
• Anti-Androgens
• Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
• Luteinizing Hormone-Releasing Hormone (LHRH) Analogs
• Immunotherapy
• Provenge

Distribution Channels Covered:

• Hospital Pharmacy
• Retail Pharmacy
• Online Sales
• Other Distribution Channels

Regions Covered:

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• Italy
• UK
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• New Zealand
• Rest of Asia Pacific
• Rest of the World
• Middle East
• Brazil
• Argentina
• South Africa
• Egypt

What our report offers:

• Market share assessments for the regional and country level segments
• Market share analysis of the top industry players
• Strategic recommendations for the new entrants
• Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
  2.4.1 Data Mining
  2.4.2 Data Analysis
  2.4.3 Data Validation
  2.4.4 Research Approach
2.5 Research Sources
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions

3 MARKET TREND ANALYSIS

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Futuristic Market Scenario

4 PORTERS FIVE FORCE ANALYSIS

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, BY DRUGS CLASS

5.1 Introduction
5.2 Chemotherapy
  5.2.1 Estramustine (Emcyt)
  5.2.2 Mitoxantrone (Novantrone)
  5.2.3 Jevtana
  5.2.4 Taxotere
5.3 Targeted Therapy
  5.3.1 Xofigo
5.4 Hormonal Therapy
  5.4.1 Anti-Androgens
    5.4.1.1 Casodex
    5.4.1.2 Xtandi
  5.4.2 Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
    5.4.2.1 Zytiga
    5.4.2.2 Gonax
    5.4.2.3 Firmagon
  5.4.3 Luteinizing Hormone-Releasing Hormone (LHRH) Analogs
    5.4.3.1 Vantas
    5.4.3.2 Eligard
    5.4.3.3 Decapeptyl
    5.4.3.4 Zoladex
    5.4.3.5 Lupron
5.5 Immunotherapy
  5.5.1 Provenge

6 GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

6.1 Introduction
6.2 Hospital Pharmacy
6.3 Retail Pharmacy
6.4 Online Sales
6.5 Other Distribution Channels

7 GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, BY GEOGRAPHY

7.1 North America
  7.1.1 US
  7.1.2 Canada
  7.1.3 Mexico
7.2 Europe
  7.2.1 Germany
  7.2.2 France
  7.2.3 Italy
  7.2.4 UK
  7.2.5 Spain
  7.2.6 Rest of Europe
7.3 Asia Pacific
  7.3.1 Japan
  7.3.2 China
  7.3.3 India
  7.3.4 Australia
  7.3.5 New Zealand
  7.3.6 Rest of Asia Pacific
7.4 Rest of the World
  7.4.1 Middle East
  7.4.2 Brazil
  7.4.3 Argentina
  7.4.4 South Africa
  7.4.5 Egypt

8 KEY DEVELOPMENTS

8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9 COMPANY PROFILING

9.1 Tolmar Inc
9.2 Teva Pharmaceutical Industries Ltd
9.3 Takeda Pharmaceutical Co. Ltd
9.4 Sanofi-Aventis
9.5 Pfizer Inc
9.6 Johnson & Johnson
9.7 Ipsen
9.8 Ferring Pharmaceuticals
9.9 Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc)
9.10 Dendreon Corporation
9.11 Bristol-Myers Squibb
9.12 Astrazeneca Plc
9.13 Astellas Pharma Inc
9.14 Active Biotech
9.15 Abbott Laboratories

List Of Tables

LIST OF TABLES

Table 1 Global Prostate Cancer Therapeutics Market Outlook, By Region (2015-2023) ($MN)
Table 2 Global Prostate Cancer Therapeutics Market Outlook, By Drugs Class (2015-2023) ($MN)
Table 3 Global Prostate Cancer Therapeutics Market Outlook, By Chemotherapy (2015-2023) ($MN)
Table 4 Global Prostate Cancer Therapeutics Market Outlook, By Estramustine (Emcyt) (2015-2023) ($MN)
Table 5 Global Prostate Cancer Therapeutics Market Outlook, By Mitoxantrone (Novantrone) (2015-2023) ($MN)
Table 6 Global Prostate Cancer Therapeutics Market Outlook, By Jevtana (2015-2023) ($MN)
Table 7 Global Prostate Cancer Therapeutics Market Outlook, By Taxotere (2015-2023) ($MN)
Table 8 Global Prostate Cancer Therapeutics Market Outlook, By Targeted Therapy (2015-2023) ($MN)
Table 9 Global Prostate Cancer Therapeutics Market Outlook, By Xofigo (2015-2023) ($MN)
Table 10 Global Prostate Cancer Therapeutics Market Outlook, By Hormonal Therapy (2015-2023) ($MN)
Table 11 Global Prostate Cancer Therapeutics Market Outlook, By Anti-Androgens (2015-2023) ($MN)
Table 12 Global Prostate Cancer Therapeutics Market Outlook, By Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists (2015-2023) ($MN)
Table 13 Global Prostate Cancer Therapeutics Market Outlook, By Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (2015-2023) ($MN)
Table 14 Global Prostate Cancer Therapeutics Market Outlook, By Immunotherapy (2015-2023) ($MN)
Table 15 Global Prostate Cancer Therapeutics Market Outlook, By Provenge (2015-2023) ($MN)
Table 16 Global Prostate Cancer Therapeutics Market Outlook, By Distribution Channel (2015-2023) ($MN)
Table 17 Global Prostate Cancer Therapeutics Market Outlook, By Hospital Pharmacy (2015-2023) ($MN)
Table 18 Global Prostate Cancer Therapeutics Market Outlook, By Retail Pharmacy (2015-2023) ($MN)
Table 19 Global Prostate Cancer Therapeutics Market Outlook, By Online Sales (2015-2023) ($MN)
Table 20 Global Prostate Cancer Therapeutics Market Outlook, By Other Distribution Channels (2015-2023) ($MN)
Table 21 North America Prostate Cancer Therapeutics Market Outlook, By Country (2015-2023) ($MN)
Table 22 North America Prostate Cancer Therapeutics Market Outlook, By Drugs Class (2015-2023) ($MN)
Table 23 North America Prostate Cancer Therapeutics Market Outlook, By Chemotherapy (2015-2023) ($MN)
Table 24 North America Prostate Cancer Therapeutics Market Outlook, By Estramustine (Emcyt) (2015-2023) ($MN)
Table 25 North America Prostate Cancer Therapeutics Market Outlook, By Mitoxantrone (Novantrone) (2015-2023) ($MN)
Table 26 North America Prostate Cancer Therapeutics Market Outlook, By Jevtana (2015-2023) ($MN)
Table 27 North America Prostate Cancer Therapeutics Market Outlook, By Taxotere (2015-2023) ($MN)
Table 28 North America Prostate Cancer Therapeutics Market Outlook, By Targeted Therapy (2015-2023) ($MN)
Table 29 North America Prostate Cancer Therapeutics Market Outlook, By Xofigo (2015-2023) ($MN)
Table 30 North America Prostate Cancer Therapeutics Market Outlook, By Hormonal Therapy (2015-2023) ($MN)
Table 31 North America Prostate Cancer Therapeutics Market Outlook, By Anti-Androgens (2015-2023) ($MN)
Table 32 North America Prostate Cancer Therapeutics Market Outlook, By Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists (2015-2023) ($MN)
Table 33 North America Prostate Cancer Therapeutics Market Outlook, By Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (2015-2023) ($MN)
Table 34 North America Prostate Cancer Therapeutics Market Outlook, By Immunotherapy (2015-2023) ($MN)
Table 35 North America Prostate Cancer Therapeutics Market Outlook, By Provenge (2015-2023) ($MN)
Table 36 North America Prostate Cancer Therapeutics Market Outlook, By Distribution Channel (2015-2023) ($MN)
Table 37 North America Prostate Cancer Therapeutics Market Outlook, By Hospital Pharmacy (2015-2023) ($MN)
Table 38 North America Prostate Cancer Therapeutics Market Outlook, By Retail Pharmacy (2015-2023) ($MN)
Table 39 North America Prostate Cancer Therapeutics Market Outlook, By Online Sales (2015-2023) ($MN)
Table 40 North America Prostate Cancer Therapeutics Market Outlook, By Other Distribution Channels (2015-2023) ($MN)
Table 41 Europe Prostate Cancer Therapeutics Market Outlook, By Country (2015-2023) ($MN)
Table 42 Europe Prostate Cancer Therapeutics Market Outlook, By Drugs Class (2015-2023) ($MN)
Table 43 Europe Prostate Cancer Therapeutics Market Outlook, By Chemotherapy (2015-2023) ($MN)
Table 44 Europe Prostate Cancer Therapeutics Market Outlook, By Estramustine (Emcyt) (2015-2023) ($MN)
Table 45 Europe Prostate Cancer Therapeutics Market Outlook, By Mitoxantrone (Novantrone) (2015-2023) ($MN)
Table 46 Europe Prostate Cancer Therapeutics Market Outlook, By Jevtana (2015-2023) ($MN)
Table 47 Europe Prostate Cancer Therapeutics Market Outlook, By Taxotere (2015-2023) ($MN)
Table 48 Europe Prostate Cancer Therapeutics Market Outlook, By Targeted Therapy (2015-2023) ($MN)
Table 49 Europe Prostate Cancer Therapeutics Market Outlook, By Xofigo (2015-2023) ($MN)
Table 50 Europe Prostate Cancer Therapeutics Market Outlook, By Hormonal Therapy (2015-2023) ($MN)
Table 51 Europe Prostate Cancer Therapeutics Market Outlook, By Anti-Androgens (2015-2023) ($MN)
Table 52 Europe Prostate Cancer Therapeutics Market Outlook, By Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists (2015-2023) ($MN)
Table 53 Europe Prostate Cancer Therapeutics Market Outlook, By Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (2015-2023) ($MN)
Table 54 Europe Prostate Cancer Therapeutics Market Outlook, By Immunotherapy (2015-2023) ($MN)
Table 55 Europe Prostate Cancer Therapeutics Market Outlook, By Provenge (2015-2023) ($MN)
Table 56 Europe Prostate Cancer Therapeutics Market Outlook, By Distribution Channel (2015-2023) ($MN)
Table 57 Europe Prostate Cancer Therapeutics Market Outlook, By Hospital Pharmacy (2015-2023) ($MN)
Table 58 Europe Prostate Cancer Therapeutics Market Outlook, By Retail Pharmacy (2015-2023) ($MN)
Table 59 Europe Prostate Cancer Therapeutics Market Outlook, By Online Sales (2015-2023) ($MN)
Table 60 Europe Prostate Cancer Therapeutics Market Outlook, By Other Distribution Channels (2015-2023) ($MN)
Table 61 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Country (2015-2023) ($MN)
Table 62 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Drugs Class (2015-2023) ($MN)
Table 63 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Chemotherapy (2015-2023) ($MN)
Table 64 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Estramustine (Emcyt) (2015-2023) ($MN)
Table 65 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Mitoxantrone (Novantrone) (2015-2023) ($MN)
Table 66 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Jevtana (2015-2023) ($MN)
Table 67 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Taxotere (2015-2023) ($MN)
Table 68 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Targeted Therapy (2015-2023) ($MN)
Table 69 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Xofigo (2015-2023) ($MN)
Table 70 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Hormonal Therapy (2015-2023) ($MN)
Table 71 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Anti-Androgens (2015-2023) ($MN)
Table 72 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists (2015-2023) ($MN)
Table 73 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (2015-2023) ($MN)
Table 74 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Immunotherapy (2015-2023) ($MN)
Table 75 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Provenge (2015-2023) ($MN)
Table 76 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Distribution Channel (2015-2023) ($MN)
Table 77 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Hospital Pharmacy (2015-2023) ($MN)
Table 78 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Retail Pharmacy (2015-2023) ($MN)
Table 79 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Online Sales (2015-2023) ($MN)
Table 80 Asia Pacific Prostate Cancer Therapeutics Market Outlook, By Other Distribution Channels (2015-2023) ($MN)
Table 81 RoW Prostate Cancer Therapeutics Market Outlook, By Country (2015-2023) ($MN)
Table 82 RoW Prostate Cancer Therapeutics Market Outlook, By Drugs Class (2015-2023) ($MN)
Table 83 RoW Prostate Cancer Therapeutics Market Outlook, By Chemotherapy (2015-2023) ($MN)
Table 84 RoW Prostate Cancer Therapeutics Market Outlook, By Estramustine (Emcyt) (2015-2023) ($MN)
Table 85 RoW Prostate Cancer Therapeutics Market Outlook, By Mitoxantrone (Novantrone) (2015-2023) ($MN)
Table 86 RoW Prostate Cancer Therapeutics Market Outlook, By Jevtana (2015-2023) ($MN)
Table 87 RoW Prostate Cancer Therapeutics Market Outlook, By Taxotere (2015-2023) ($MN)
Table 88 RoW Prostate Cancer Therapeutics Market Outlook, By Targeted Therapy (2015-2023) ($MN)
Table 89 RoW Prostate Cancer Therapeutics Market Outlook, By Xofigo (2015-2023) ($MN)
Table 90 RoW Prostate Cancer Therapeutics Market Outlook, By Hormonal Therapy (2015-2023) ($MN)
Table 91 RoW Prostate Cancer Therapeutics Market Outlook, By Anti-Androgens (2015-2023) ($MN)
Table 92 RoW Prostate Cancer Therapeutics Market Outlook, By Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists (2015-2023) ($MN)
Table 93 RoW Prostate Cancer Therapeutics Market Outlook, By Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (2015-2023) ($MN)
Table 94 RoW Prostate Cancer Therapeutics Market Outlook, By Immunotherapy (2015-2023) ($MN)
Table 95 RoW Prostate Cancer Therapeutics Market Outlook, By Provenge (2015-2023) ($MN)
Table 96 RoW Prostate Cancer Therapeutics Market Outlook, By Distribution Channel (2015-2023) ($MN)
Table 97 RoW Prostate Cancer Therapeutics Market Outlook, By Hospital Pharmacy (2015-2023) ($MN)
Table 98 RoW Prostate Cancer Therapeutics Market Outlook, By Retail Pharmacy (2015-2023) ($MN)
Table 99 RoW Prostate Cancer Therapeutics Market Outlook, By Online Sales (2015-2023) ($MN)
Table 100 RoW Prostate Cancer Therapeutics Market Outlook, By Other Distribution Channels (2015-2023) ($MN)